DDInter1140 DDInter1658
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Mefloquine {u} (Compound) binds {v} (Gene) ACHE
Mefloquine {u} (Compound) upregulates {v} (Gene) DDIT4
Mefloquine {u} (Compound) downregulates {v} (Gene) RRP12
Mefloquine {u} (Compound) causes {v} (Side Effect) Leukocytosis
Mefloquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metoclopramide
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Mefloquine (Compound) resembles Flecainide (Compound)
Mefloquine (Compound) binds ACHE (Gene)
Mefloquine (Compound) upregulates DDIT4 (Gene)
Mefloquine (Compound) downregulates RRP12 (Gene)
Mefloquine (Compound) causes Leukocytosis (Side Effect)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Mefloquine may lead to a major life threatening interaction when taken with Ibutilide
Mefloquine may lead to a major life threatening interaction when taken with Pimozide